Tau oligomers as potential targets for immunotherapy for Alzheimer's disease and tauopathies.
about
Protein misfolding and aggregation in Alzheimer's disease and type 2 diabetes mellitusFLZ alleviates the memory deficits in transgenic mouse model of Alzheimer's disease via decreasing beta-amyloid production and tau hyperphosphorylationCerebral Microvascular Accumulation of Tau Oligomers in Alzheimer's Disease and Related Tauopathies.Oligomeric tau-targeted immunotherapy in Tg4510 mice.Specific calpain inhibition by calpastatin prevents tauopathy and neurodegeneration and restores normal lifespan in tau P301L miceA generic method for design of oligomer-specific antibodies.The pathophysiology of repetitive concussive traumatic brain injury in experimental models; new developments and open questionsTargeting intrinsically disordered proteins in rational drug discovery.Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.Tau-Directed Immunotherapy: A Promising Strategy for Treating Alzheimer's Disease and Other Tauopathies.Rapid accumulation of endogenous tau oligomers in a rat model of traumatic brain injury: possible link between traumatic brain injury and sporadic tauopathiesCharacterization of Early Pathological Tau Conformations and Phosphorylation in Chronic Traumatic Encephalopathy.Tau oligomers as potential targets for Alzheimer's diagnosis and novel drugsImmunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.Abolishing Tau cleavage by caspases at Aspartate421 causes memory/synaptic plasticity deficits and pre-pathological Tau alterations.Potential mechanisms and implications for the formation of tau oligomeric strains.Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach.The tyrosine phosphatase PTPN13/FAP-1 links calpain-2, TBI and tau tyrosine phosphorylation.Tau Oligomers Associate with Inflammation in the Brain and Retina of Tauopathy Mice and in Neurodegenerative Diseases.Analysis of isoform-specific tau aggregates suggests a common toxic mechanism involving similar pathological conformations and axonal transport inhibition.Calpain-2 as a therapeutic target for acute neuronal injury.Tau Oligomers in Sera of Patients with Alzheimer's Disease and Aged Controls.Overview of immunotherapy in Alzheimer's disease (AD) and mechanisms of IVIG neuroprotection in preclinical models of AD.
P2860
Q28397425-5C5684E0-3FCA-495E-B8CC-B769ACC127C9Q28534810-AAE9FDF3-BE41-45E7-94D0-A1FC5F30BA4EQ33714234-38D3A923-B843-47E0-88F1-CCA8106B473FQ33846761-8A890569-C7C0-46CF-9E7F-37B065008CC2Q33865294-49D6DF0F-5D52-4470-9E27-DD79120C3C98Q35117526-97DD2C91-4B8E-4554-9D43-14EBC3DC779CQ35706415-DCF77A14-CCB6-4640-B0A2-66270211BD4BQ35835558-82A66DDC-48EE-48B4-913A-AB947A43E25DQ36484413-A3A959AF-528B-4F57-B2E9-23CD6E358822Q36558485-72F123AF-BF0A-486E-B4CD-1B6F202D82BDQ36910217-693ACE63-6034-4DB4-8975-A729E870A235Q36963598-6BA476F7-F42D-4F64-9DD4-B656BF48A646Q37256805-69311B3C-28E3-4B4A-B726-DA3690DD0A1BQ37984574-7B70528B-647F-4B97-A740-6EBA9C0C47FDQ38079317-7451ED1F-743E-4C53-A950-E4BA67E22E04Q38634954-64D43D16-3125-49BC-96C9-C85F4558A2C2Q38960046-A97E0E45-074F-4B7D-BFED-628A84E22B92Q40141995-45742820-7BD0-4C8F-817A-D4EE0BEE890CQ41718094-92C19CC9-891C-4C15-B68F-768101FD517BQ42355513-9ED88F50-4059-425F-9C05-F1E0CC5CCE6FQ42714396-FBFA1C44-CBD3-4269-8AA0-A2C9F451E3AFQ47370941-FCDEF88C-157B-4070-B87C-3D4AFC554732Q47737194-1F179B04-78CC-4F55-9854-8E30AEF1F98FQ48585657-1A91F07C-4857-4BAB-81D8-1843DF081565
P2860
Tau oligomers as potential targets for immunotherapy for Alzheimer's disease and tauopathies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Tau oligomers as potential tar ...... mer's disease and tauopathies.
@en
Tau oligomers as potential tar ...... mer's disease and tauopathies.
@nl
type
label
Tau oligomers as potential tar ...... mer's disease and tauopathies.
@en
Tau oligomers as potential tar ...... mer's disease and tauopathies.
@nl
prefLabel
Tau oligomers as potential tar ...... mer's disease and tauopathies.
@en
Tau oligomers as potential tar ...... mer's disease and tauopathies.
@nl
P2093
P1476
Tau oligomers as potential tar ...... imer's disease and tauopathies
@en
P2093
C A Lasagna-Reeves
G R Jackson
P304
P356
10.2174/156720511796717177
P577
2011-09-01T00:00:00Z